Navigation Links
Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
Date:1/21/2008

MADISON, Wis., Jan. 21 /PRNewswire/ -- While urinary stents and catheters can be life-saving medical devices, 40 percent of patients end up with bacterial infections. With 100 million placed in patients each year, this means that doctors must treat 40 million device-associated infections annually. Nerites Corporation is testing its unique new technology for preventing these dangerous infections, with funding from a $100,000 small business innovation research grant (SBIR) from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH).

The study will determine whether Nerites novel polymer coatings can prevent biofilm growth, the source of most infections on urinary stents and catheters. Biofilms grow on the surface of the device and provide an anchor for bacteria, which then recruit other bacteria and cause infection.

"Current methods to prevent biofilms are expensive, often ineffective and can promote antibiotic resistance," said Thomas J. Mozer, Ph.D., CEO and President of Nerites Corporation. "This money will help us test our coating technology, which we believe will block biofilm formation reliably and inexpensively, without antibiotics or biocides."

About Nerites: Nerites Corporation develops novel tissue repair products as well as advanced coatings for implanted medical devices and device uses on skin based on unique "wet" adhesive compounds. These synthetic compounds are based upon research by Dr. Phil Messersmith at Northwestern University's Department of Biomedical Engineering on how marine mussels bind to surfaces underwater, are a breakthrough advance in biologically-compatible adhesives that provide completely new options for tissue repair, skin adhesives, and device coatings. Nerites is based in Madison Wisconsin. (http://www.nerites.com)


'/>"/>
SOURCE Nerites Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
3. Novadaqs SPY System receives clearance for use in organ transplant surgery
4. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
5. e-Health Card Terminal From SCM Microsystems Receives GEMATIK Certification
6. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
7. LifeMasters Receives Full URAC Disease Management Accreditation
8. Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report
9. Glory Foods Receives Heart Healthy Certification
10. TeamStaff Receives Nasdaq Determination Letter
11. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology: